SCR-LIP-000676 · Claim · machine-readable JSON →

Lymphatic dysfunction in lipedema may be more pronounced in severe disease or with longer disease duration.

General proposition consolidated from 5 earlier single-paper claims; each study's own result is shown as its finding.

Claim at a glance
Type
clinical association
Knowledge state
Emerging
Evidence certainty
moderate (GRADE)
Evidence
5 source(s)
Dates
2026-11-20 → 2026-11-20

Structured evidence, machine-compiled — not a verdict.

Evidence over time

20192022Uncovering Lymphatic Transport Abnormalities in Patients with Primary Lipedema — Gould et al. (2019) · consistentNon-contrast MR Lymphography of lipedema of the lower extremities — Cellina et al. (2020) · consistentIndocyanine green lymphography as novel tool to assess lymphatics in patients with lipedema — Buso et al. (2021) · refiningUpdate in the management of lipedema — FORNER-CORDERO et al. (2021) · refiningLymphatic function and anatomy in early stages of lipedema — Rasmussen et al. (2022) · consistent

Evidence (5)

Context (PECO)

Populationlipedema patients, stages 1–4 (n=19)
Conditionlipedema
Exposuresevere lipedema (stage 3/4)
Comparatormild/moderate lipedema (stage 1/2)
Outcomelymphatic transport index (TI) score
Scopeauto-ingested from Layer 1 surveillance

Answers these questions

Gaps & caveats

Change log